Management and outcome of Bacille Calmette-Guérin vaccine adverse reactions  by Venkataraman, Aishwarya et al.
M
r
A
A
a
b
a
A
R
R
A
A
K
B
L
C
T
O
1
s
B
t
c
[
a
h
b
U
f
h
0Vaccine 33 (2015) 5470–5474
Contents lists available at ScienceDirect
Vaccine
j o ur na l ho me  page: www.elsev ier .com/ locate /vacc ine
anagement  and  outcome  of  Bacille  Calmette-Guérin  vaccine  adverse
eactions
ishwarya  Venkataramana, Michael  Yusuffa,  Susan  Liebeschuetza,  Anna  Riddell a,
ndrew  J.  Prendergasta,b,∗
Barts Health NHS Trust, London, UK
Centre for Paediatrics, Blizard Institute, Queen Mary University of London, London, UK
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 15 March 2015
eceived in revised form 26 July 2015
ccepted 29 July 2015
vailable online 12 August 2015
eywords:
CG vaccine
ymphadenitis
omplications
reatment
utcome
a  b  s  t  r  a  c  t
Background:  Bacille  Calmette-Guérin  (BCG)  vaccine  is one  of the most  widely  used  vaccines  globally.
Management  of local  BCG  complications  (injection  site reactions  and suppurative  or non-suppurative
lymphadenitis)  varies  between  clinicians,  and the  optimal  approach  remains  uncertain.
Aim:  To  determine  the clinical  features,  management  and  outcome  of  BCG  complications  at  two  large
acute  hospitals  in  London,  United  Kingdom.
Methods:  All  children  presenting  with  complications  of  BCG  vaccination  between  January  2008  and
December  2013  were  included  in  this  observational  study.  Medical  and  electronic  laboratory  records
were  reviewed  to  determine  clinical  features,  treatment  and  outcome.
Results:  Sixty  children  presented  with  adverse  reactions.  Two-thirds  (65%)  presented  with  BCG  lym-
phadenitis,  one-third  (30%)  presented  with  injection  site  complications  and  two  children  (3%) presented
with  both  injection  site  reaction  and  lymphadenitis;  only  one  child  (2%) had  disseminated  BCG  disease.
The  majority  (88%)  of  children  with  injection  site  reactions  were  managed  conservatively;  overall,  95%
showed  complete  resolution  within  6 months.  Among  children  with  lymphadenitis,  46%  were  man-
aged  conservatively,  whilst  54%  had  anti-tuberculous  therapy  and/or  a procedure  (aspiration  mostly,  or
surgery);  complete  resolution  was  seen  in  59%  of cases.
Conclusions:  Injection  site reactions  and  non-suppurative  lymphadenitis  were  generally  managed  con-
servatively,  with  good  outcomes.  There  was  more  variation  in management  and  outcome  of  suppurative
lymphadenitis  and the  optimal  approach  remains  uncertain.
©  2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).. Introduction
The Bacille Calmette-Guérin (BCG) vaccine is a live attenuated
train of Mycobacterium bovis, ﬁrst used in humans in 1921. Overall,
CG vaccine reduces the risk of pulmonary and extra-pulmonary
uberculosis (TB) by approximately 50% [1–3], but it has 64% efﬁ-
acy against TB meningitis and 78% against disseminated TB disease
1,2,4]. BCG vaccine also provides some protection against leprosy
nd non-tuberculous mycobacterial infections [5]. In addition, it
as been used in the treatment of superﬁcial carcinoma of the
ladder [6,7].
∗ Corresponding author at: Centre for Paediatrics, Blizard Institute, Queen Mary
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article uA typical reaction following BCG vaccination is a red indurated
area at the injection site, which may  subsequently ulcerate, then
form a crust, which falls off after about 6 weeks leaving a small scar.
Axillary lymphadenopathy (<1 cm)  is also a normal response to BCG
vaccination [4,8]. Adverse reactions to BCG vaccine are reported in
1–10% of vaccinees, but are likely to be substantially underreported
[9,10]. Adverse reactions are usually seen within the ﬁrst 6 months
of vaccination but can present beyond 12 months [10,11]. There
appears to be an association between adverse reactions and the
strain of BCG administered [10,12–15]. Worldwide, the most com-
monly used vaccine strains currently are Statens Serum Institute
(SSI) Copenhagen strain 1331 (Danish 1331), Tokyo 172-1 and Rus-
sian BCG-I [15]. In the United Kingdom, Danish 1331 has been in use
since 2004. Depending on the immunogenicity generated in animal
models, strains have been termed strong (e.g. Danish 1331) or weak
(e.g. Tokyo 172) [12,15], with strong strains associated with more
adverse reactions [12,13,15].
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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BCG complications can cause signiﬁcant morbidity in chil-
ren and anxiety in their parents. Local adverse reactions include
egional suppurative and non-suppurative lymphadenitis, injec-
ion site abscesses, persistent injection site reactions, ulceration
nd uncommonly keloid reactions [3,10,16]. Systemic adverse reac-
ions are rare and include osteomyelitis/osteitis and disseminated
CG disease [3,10]. Systemic dissemination is of particular risk in
hildren with primary immune deﬁciencies or human immuno-
eﬁciency virus (HIV) infection [17]. Local and regional adverse
eactions occur most frequently and the majority are self-limiting
4,17]. However, many clinicians advocate treatment, including use
f antimicrobials, needle aspiration and/or surgery [4,11,17] and
ractice is likely to vary substantially across sites.
Here we describe our experience of BCG vaccine-associated
dverse reactions in children referred to two large hospitals in
ondon, United Kingdom.
. Methods
.1. Study subjects
We  included all children presenting between January 2008 and
ecember 2013 with complications associated with BCG vacci-
ation to two  large acute hospitals (Royal London Hospital and
ewham University Hospital) in east London, UK. In the UK, BCG
accination is usually given in the community, once the baby
s discharged home after birth. Children with BCG complications
re mostly seen by general practitioners initially; those needing
pecialist review are referred to hospital. We  identiﬁed children
hrough clinic lists (general paediatrics, infectious diseases and
B clinics) and referral letters (from general practitioners or other
pecialists) and reviewed their medical records and electronic labo-
atory data. Our study includes children who were initially referred
o other specialties (general surgery and orthopaedic surgery) but
ere subsequently referred to a paediatric clinic for review. Data
n the following variables were collected onto a proforma: baseline
emographics, age at presenting to hospital with adverse reactions,
etails of vaccination procedure (if available), type of complication,
icrobiological investigations undertaken, management approach
nd outcome.
Formation of a small scar after vaccination was  considered a
ormal reaction. Complications were deﬁned as local (injection site
eaction, isolated lymphadenitis or both) or systemic (osteomyeli-
is/osteitis and disseminated BCG disease). Lymphadenopathy
1 cm in size and presence of an abscess/ulcer at the injection site
eyond 12 weeks were considered to be complications. Treatment
iven was divided into conservative (watch and wait), medical ther-
py (antimicrobials), needle aspiration or surgery. Outcome was
eﬁned as either complete resolution (a small scar at the injection
ite within 6 months of presentation) or healing with complications
sinus, ulcer, keloid, persistent lymphadenitis beyond 6 months or
igniﬁcant scarring requiring referral to a plastic surgeon or der-
atologist), as judged by the treating clinician. Children who  were
een in the clinic with a normal oozing injection site (mostly due
o parental anxiety) were discharged after reassurance and were
xcluded from the study. Children with BCG site reactions due to
awasaki disease were not included in this study. Statistical anal-
sis was performed using SPSS.
.2. Ethical approvalEthical approval was obtained from the Joint Research Manage-
ent Ofﬁce of Barts Health NHS Trust. Caregiver consent was not
equired.e 33 (2015) 5470–5474 5471
3. Results
3.1. Baseline characteristics
Sixty children presented over a 6 year period at a median age of 6
months (interquartile range (IQR) 4–7 months; range: 2 months–15
years) with BCG vaccine complications. Median age at vaccination
was 6 weeks (IQR 2–6 weeks; range: 2 days–15 years) and the male
to female ratio was 1.3:1. Forty-one children (68%) were ≤6 months
of age at the time of presentation.
3.2. Type of complications
Fifty-nine (98%) children presented with local complications
and one (2%) with systemic complications. Eighteen children (30%)
presented with isolated injection site reactions, 39 (65%) had iso-
lated axillary lymphadenitis (suppurative or non-suppurative) and
2 (3%) had an injection site reaction with lymphadenitis. One
child (2%) presented with a BCG site abscess and lymphadenitis
and subsequent BCG osteomyelitis, associated with abnormal liver
function, indicative of systemic BCG disease.
3.3. Management approach
Thirty-ﬁve (58%) children were conservatively managed, 15
(25%) received medical therapy and 10 (17%) were managed by
aspiration alone (Fig. 1). Of the 15 who  received medical ther-
apy, 14 were treated with anti-tuberculous therapy (ATT) and
one received co-amoxiclav. Of the 14 children who received ATT,
4 also underwent aspiration and 2 had surgical intervention.
Nine children received single ATT (isoniazid) and ﬁve children
received two-drug ATT (isoniazid and rifampicin). Samples from
16 children were sent for microbiological investigation; BCG was
isolated from 8/15 (53%) children with available microbiology
results.
3.4. Outcomes by clinical presentation
3.4.1. Injection site reaction
Eighteen (30%) children presented with signiﬁcant injection site
reactions. Of these, 10/18 (55%) were less than 6 months of age at
the time of presentation. Sixteen children (88%) were managed con-
servatively, one (6%) received ATT and one (6%) was  managed by
aspiration alone. Complete resolution was seen in 17/18 (95%) chil-
dren. One child (5%) was left with persistent scarring at the injection
site and was referred to a plastic surgeon for further management
(Fig. 2).
3.4.2. Lymphadenitis
Thirty-nine (65%) children presented with isolated axillary
lymphadenitis (20 with suppurative lymphadenitis; 19 with non-
suppurative lymphadenitis). Of these, 28/39 (72%) were less than
6 months of age at the time of presentation. Of those with
non-suppurative lymphadenitis, 15/19 (78%) were managed con-
servatively; 2 (11%) received ATT (one of whom also had aspiration)
and 2 (11%) underwent aspiration alone (Fig. 3). Complete resolu-
tion was seen in 17/19 (89%) children; two (11%) had persistent
lymphadenitis 6 months after presentation. Of those with suppura-
tive lymphadenitis, 3/20 (15%) were treated conservatively, 10/20
(50%) received ATT (of whom 2 had aspiration and 1 had surgical
intervention), and 7/20 (35%) underwent aspiration alone (Fig. 4).
Complete resolution was seen in only 6/20 (30%) children; 13/20
(65%) had some residual complication and one child (5%) was  lost
to follow-up after 3 months.
5472 A. Venkataraman et al. / Vaccine 33 (2015) 5470–5474
Fig. 1. Number of children with BCG vaccine complications and their treatment.
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Fig. 3. Management and outcome of children with non-suppurative lymphadenitis.Fig. 2. Management and outcome of children with injection site reaction.
.4.3. Injection site reaction with lymphadenitis
Two children (3%) presented with signiﬁcant injection site
eaction and lymphadenitis. One child, who had axillary and sup-
aclavicular lymphadenitis together with an injection site reaction,
as treated ATT and underwent aspiration; he was left with signif-
cant ulceration at the injection site which later resulted in a large
ersistent scar. He was referred to a plastic surgeon and dermatol-
gist for further management. The second child, who had axillary
ymphadenopathy and an injection site reaction, was managed con-
ervatively and recovered completely.
.4.4. Systemic complications
One child (2%) presented with swelling of the left elbow. He
nderwent surgery for septic arthritis and was found to have
xtensive humeral osteomyelitis. Samples collected at operation
dentiﬁed Mycobacterium tuberculosis complex by PlexID (Abbott),
nd BCG was subsequently cultured from the same sample. He
as treated with ATT (rifampicin, isoniazid and ethambutol;
CG isolate resistant to pyrazinamide) and later ciproﬂoxacin
as added. Investigations for severe combined immunodeﬁciency
Fig. 4. Management and outcome of children with suppurative lymphadenitis.
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SCID), human immunodeﬁciency virus (HIV) and chronic granu-
omatous disease (CGD) were negative; evaluation of peripheral
lood mononuclear cell cytokine production showed normal pro-
uction of IL-17 and IL-12, but reduced production of IFN-gamma
ollowing polyclonal stimuli, suggesting a potential defect in
acrophage/T-cell signalling; he subsequently started subcuta-
eous interferon-gamma therapy.
. Discussion
In this study of children presenting to two  large London
ospitals with BCG vaccine complications over a 6-year period,
pproximately one-third presented with injection site complica-
ions and two-thirds presented with BCG lymphadenitis; only one
hild had disseminated BCG disease. Children with injection site
omplications and non-suppurative lymphadenitis were usually
anaged conservatively and the vast majority showed complete
esolution within 6 months. Among children with suppurative lym-
hadenitis, there was more variation in management approach:
nly 15% were managed conservatively, whilst the majority had
ntituberculous therapy and/or a procedure (aspiration mostly, or
urgery); complete resolution was seen in only 30% of cases.
The vast majority of children had local BCG complications and
ost presented before 6 months of age. Overall, local complications
ccur in approximately 1:1000 people who receive BCG [4,18], but
he risk is higher at younger ages [11,17], likely related to impaired
h1 immunity in early life. Other factors, such as dose and strain
f vaccine, administration technique and underlying immunodeﬁ-
iency or HIV also impact frequency of complications [12,15,18,19].
n injection site abscess can develop up to 30 days after injection
4,16], and was the reason for referral in one-third of cases in our
tudy. A conservative approach is usually adopted for local injection
ite reaction or abscess [3]. Consistent with this, the vast major-
ty (88%) children referred with isolated injection site reactions in
he current study were managed conservatively. The outcome was
omplete resolution within 6 months in all cases, and a ‘watch and
ait’ approach is therefore suitable for these cases.
Management of BCG lymphadenitis, especially suppurative
ymphadenitis, still remains unclear and controversial [8,17]. Non-
uppurative lymphadenitis may  be considered part of the normal
ourse of BCG vaccination, usually resolving spontaneously over
 few weeks to months without sequelae [4,8,17,18]. Ipsilateral
xillary nodes are most commonly enlarged, but supraclavicular,
uchal and cervical nodes can also be involved and may  be consid-
red normal variants [3,13]. Diagnosis is clinical and the absence
f any constitutional symptoms is usually sufﬁcient to differen-
iate suppurative and non-suppurative lymphadenitis. However,
on-suppurative lymphadenitis progresses to suppurative lym-
hadenitis in about 15–30% of cases [8,20], and these nodes can
upture, leading to sinus and ﬁstula formation. Healing in such cases
ypically takes many months and residual complications may  be
een [17,21]. In our study, half of children referred for BCG lym-
hadenitis had evidence of suppuration and treatment approach
aried between conservative management, anti-tuberculous ther-
py, node aspiration, or combined ATT and aspiration.
The efﬁcacy of anti-tuberculous therapy in treating local com-
lications of BCG is unclear [4,17,22]. Use of ATT is limited by the
ack of penetration of drugs into the abscess cavity [4] and inherent
esistance of M.  bovis to pyrazinamide [17,22]. Rifampicin resis-
ance can develop in BCG during treatment [22]. Moreover, routine
se of antimicrobials does not reduce the frequency of suppura-
ion in children with non-suppurative lymphadenitis [4,21]. Since
bscess-forming lymphadenitis is associated with increased mor-
idity (such as sinus formation, perforation and ulceration), which
an persist for several months, needle aspiration is often advisede 33 (2015) 5470–5474 5473
[4,8,17,20]. In a randomized study from Iran, needle aspiration
led to greater regression of lymphadenitis at 2, 4 and 6 months
compared to no intervention, and reduced the risk of sinus forma-
tion, although some infants needed repeated aspirations [4,23]. A
small number (<5%) of children who  undergo aspiration may  sub-
sequently require surgical intervention [4,23]. In our study, needle
aspiration was done in children who either presented with a large
abscess at the injection site or a ﬂuctuant node on examination. It
was performed by a doctor in the outpatient clinic (predominantly
at one hospital only) using local anaesthetic spray and a 21-ga nee-
dle. Of the children who  underwent aspiration, one developed a
sinus, but it is unknown whether this was related to the aspiration
procedure.
Although surgical excision is likely to be curative in suppura-
tive lymphadenitis and might reduce the healing time, it requires
general anaesthesia, which carries a risk in itself [4,8,17,24]. Surgi-
cal excision is not therefore recommended as a routine ﬁrst-line
approach; needle aspiration is considered a safer option [8,23].
Surgery might be needed where aspiration has failed or when the
nodes have discharged spontaneously forming a sinus [8,23,24].
The addition of ATT to surgical excision has not been found to be
beneﬁcial [4,24]. Only one child with local complications in our
study had surgical excision; he presented with recurrent suppura-
tive lymphadenitis despite ATT and three needle aspirations.
Systemic complications of BCG vaccine are extremely rare in
developed countries. They can present as osteitis or dissemi-
nated BCG disease. The incidence of osteitis/osteomyelitis has
been reported as 1–700 per million vaccinated children and
depends on the vaccine strain used [12,14,15,25,26]. Progno-
sis of BCG osteitis/osteomyelitis is generally good without any
sequelae [9,10,25,27]. The incidence of disseminated disease is
estimated to be about 2 to 3.4 per million vaccinated children
[3,9,17,25,28], although one Canadian study [29] reported a rate
of 205 per million doses among children from TB-endemic com-
munities. Disseminated disease is associated with case fatality
rates of 80–85% [3,4,10,17,30]. Systemic complications usually
occur within 6 months of vaccination and are most commonly
seen in children with underlying primary immunodeﬁciency
(severe combined immunodeﬁciency, chronic granulomatous dis-
ease, disorders of the gamma-IFN/IL-12 pathway, or a group of
conditions termed Mendelian Susceptibility to Mycobacterial Dis-
ease (MSMD)) [4,17,19,28–30]. In areas of high HIV prevalence,
disseminated BCG disease in the context of undiagnosed infant
HIV infection can occur [22,30]. Occasionally, a BCG immune
reconstitution inﬂammatory syndrome (IRIS) can occur in previ-
ously vaccinated children after initiation of antiretroviral therapy,
presenting as either local site reactions, lymphadenitis or sys-
temic disease [22,31]. Rarely, systemic reactions can be idiopathic
[4,19,30,32]. The patient in our study with systemic complication
was investigated for possible immunodeﬁciency and had reduced
gamma-IFN production in response to polyclonal stimulation, indi-
cating a potential immunodeﬁciency, which is currently being
better characterized.
This study described all available cases of BCG complications
seen over a 6-year period at two  large hospitals, but has some lim-
itations. First, this was a hospital-based study, and we  are unable
to provide an estimate of the overall complication rate associated
with BCG vaccination, since the majority of children with mild
complications are managed in the community. Second, this was  a
retrospective study and management approach varied by site and
by individual physician practice; we are therefore unable to com-
ment meaningfully on whether the management approach adopted
inﬂuenced outcome.
In summary, one-third of children referred with BCG compli-
cations had injection site reactions; these were mostly managed
conservatively and almost all resolved completely, supporting
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he generally adopted ‘watch and wait’ approach for this type
f complication. Two-thirds of children were referred with lym-
hadenitis following BCG vaccination; in half of these cases, there
as evidence of suppuration. There is no clear consensus about
he management of suppurative BCG lymphadenitis; the approach
aken in our hospitals varied between cases and only one-third
f children had complete resolution. Our experience with aspira-
ion is that it is easy to perform in an outpatient setting and is
ell tolerated by infants and their parents, but whether it reduces
he need for surgery or hastens recovery is unknown. Surgery is
arely required and should be reserved for cases where repeat
spirations have failed and deﬁnitive node removal is required. Dis-
eminated BCG disease is rare but children should be investigated
or underlying immunodeﬁciency and referred to a specialist centre
or management.
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